TCM
KPRX icon

Tuttle Capital Management’s Kiora Pharmaceuticals KPRX Stock Holding History

Tuttle Capital Management’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50
Closed -$41K – 127
2021
Q3 		$41K Buy
+50
New +$42.5K 0.05% 116

Other funds holding KPRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Tuttle Capital Management's KPRX Position: Q4 2021 in Review

Tuttle Capital Management sold out of Kiora Pharmaceuticals (KPRX) in Q4 2021, closing a stake of 50 shares — an estimated $41K sold.

Tuttle Capital Management first reported a position in KPRX in Q3 2021 and held it in 1 quarter. The position peaked at $41K in Q3 2021. 11 funds tracked by Wall St. Rank hold KPRX as of Q4 2021.

  • Tuttle Capital Management reported no remaining Kiora Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Tuttle Capital Management sold 50 Kiora Pharmaceuticals shares in Q4 2021, an estimated $41K.
  • Tuttle Capital Management first reported a position in Kiora Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Tuttle Capital Management's Kiora Pharmaceuticals position peaked at $41K in Q3 2021.
  • 11 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q4 2021.

Based on Tuttle Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.